Here, in pooled analyses with TCLs/TCLs + IFNγ and FTDs (n = 177), the proportion of tumor-reactive CD4+ TILs was similar across all cohorts, and tumor-specific CD4+ T cell responses were detected in over 50% of patients in each clinical cohort (range 58% in OC to 71% in RCC) (Figure 1B). This evidence concerns the gene IFNG and neoplasm.